FINWIRES · TerminalLIVE
FINWIRES

$IMMP

4 stories mentioning IMMP

Every FINWIRES story that references IMMP, newest first.

Sectors

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.

$GDRX$GSK$IMMP$JANX$NVO
Sectors

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 2.9%.GoodRx (GDRX) shares climbed up 3.8% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 2.2%.Immutep (IMMP) shares doubled after the firm said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.

$GDRX$IMMP$JANX$NVO
Sectors

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Health care stocks were rising pre-bell Wednesday with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Mesoblast (MESO) shares were up more than 4% after the company said it acquired an exclusive worldwide license to a chimeric antigen receptor technology platform for augmentation of therapeutic mesenchymal lineage stromal cell products.ARS Pharmaceuticals (SPRY) stock was up more than 1% after the company said Health Canada has approved its neffy 2mg nasal spray for the emergency treatment of anaphylaxis.Immutep (IMMP) shares rose by more than 178% after the company said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa for the treatment of soft tissue sarcoma, a rare cancer.

$IBB$IMMP$MESO$SPRY$XLV
Wire

Immutep's FDA Orphan Drug Designation for Rare Cancer Treatment Sends Shares Soaring Premarket

Immutep (IMMP) said early Wednesday that the United States Food and Drug Administration has granted orphan drug designation to eftilagimod alfa for the treatment of soft tissue sarcoma, a rare cancer.Shares of the company surged more than 58% in recent premarket activity.The move follows clinical data from a phase 2 trial that evaluated efti in combination with radiotherapy and Keytruda (pembrolizumab). In 38 patients, the study met its primary endpoint, demonstrating a median tumor hyalinization/fibrosis of almost 52%, exceeding the pre-specified target of 35% and historical benchmarks of about 15% with radiotherapy alone. Tumor hyalinization/fibrosis refers to healing.The company said the results were observed across multiple sarcoma subtypes and showed immune activation consistent with efti, with a favourable safety profile and no delays to planned surgery.Price: $0.495, Change: $+0.1838, Percent Change: +58.80%

$IMMP